Australia markets closed

AbbVie Inc. (ABBV)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
158.00-0.25 (-0.16%)
At close: 04:03PM EDT
158.00 0.00 (0.00%)
After hours: 07:47PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close158.25
Bid0.00 x 1000
Ask0.00 x 800
Day's range156.36 - 159.70
52-week range134.09 - 175.91
Avg. volume6,411,436
Market cap278.734B
Beta (5Y monthly)0.59
PE ratio (TTM)23.83
EPS (TTM)6.63
Earnings date27 Apr 2023 - 01 May 2023
Forward dividend & yield5.92 (3.74%)
Ex-dividend date13 Apr 2023
1y target est163.87
  • Motley Fool

    Better Growth Stock: Vertex Pharmaceuticals vs. AbbVie

    Vertex Pharmaceuticals (NASDAQ: VRTX) and AbbVie (NYSE: ABBV) both beat last year's bear market. Vertex and AbbVie also happen to offer a lot of growth potential. Vertex has a new potential blockbuster drug on the horizon.

  • PR Newswire

    Allergan Aesthetics* to showcase 360° approach to clinical practice, aesthetic products, and patients with expert-led symposia at AMWC 2023

    Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, will be showcasing its customer-centric 'Discover Your 360°' approach to aesthetics at the 21st Anti-Aging and Aesthetics Medicine World Congress (AMWC) in Monaco from 30 March - 1 April 2023, supporting practitioners to help patients 'unlock their individuality' in an evolving world. Events include two Allergan Medical Institute (AMI) symposia, Meet the Expert sessions and an interactive exhibition booth that practitioners can explore. Throug

  • Motley Fool

    Better Growth Stock: AbbVie vs. Pfizer

    AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are two of the world's biggest pharmaceutical companies, and the similarities don't end there. The case for AbbVie as a growth stock can't avoid two issues: the decline of Humira, and the stagnation of its oncology portfolio.